“Merck Sharp”

IIC - International Review of Intellectual Property and Competition Law, Feb 2018

Merck Sharp & Dohme Corporation v. Comptroller General of Patents, Designs and Trade Marks Regulation (EC) No 469/2009, Arts. 3(b), 10(3) Directive 2001/83/EC, Art. 28(4)

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1007%2Fs40319-018-0686-2.pdf

“Merck Sharp”

Regulation (EC) No D E C I S I O N P A T E N T L A W European Union ''Merck Sharp'' Merck Sharp Designs Trade Marks 1. Article 3(b) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products is to be interpreted as meaning that an end of procedure notice issued by the reference Member State in accordance with Article 28(4) of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, as amended, as regards pharmacovigilance, by Directive 2010/84/EU of the European Parliament and the Council of 15 December 2010, before the expiry of the basic patent, as defined in Article 1(c) of Regulation No 469/2009, may not be treated as equivalent to a marketing authorisation within the meaning of Article 3(b) of that regulation, with the result that a supplementary protection certificate may not be obtained on the basis of such a notice. 2. Article 10(3) of Regulation No 469/2009 is to be interpreted as meaning that the fact that no marketing authorisation has been granted by the Member State concerned at the time the supplementary protection certificate application is lodged in that Member State does not constitute an irregularity that can be cured under that provision. Supplementary protection certificate use; Conditions for obtaining; Grant or rejection authorisation; Medicinal products for human; Basic patent; Marketing


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007%2Fs40319-018-0686-2.pdf

Merck Sharp & Dohme Corporation v. Comptroller General of Patents, Designs and Trade Marks Regulation (EC) No 469/2009, Arts. 3(b), 10(3) Directive 2001/83/EC, Art. 28(4). “Merck Sharp”, IIC - International Review of Intellectual Property and Competition Law, 2018, 348-348, DOI: 10.1007/s40319-018-0686-2